Filing Flows › Theravance Biopharma (TBPH) › Q1 2026 › vs Q1 2025
Theravance Biopharma (TBPH) Q1 2026 vs Q1 2025 (year over year)
Theravance Biopharma's revenue rose $2.3M (+15%) from $15.4M in Q1 2025 to $17.7M in Q1 2026.
Theravance Biopharma, Q1 2026: revenue $17.7M (+15% year over year), operating margin -53.6%, net loss $4.9M, operating cash flow $73.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $17.7M | $15.4M | $2.3M | +15% |
| Other income, net | $3.0M | $296K | $2.7M | +918% |
| Income tax benefit | $1.5M | $559K | $978K | +175% |
| Net loss | $4.9M | $13.6M | −$8.6M | -64% |
| Costs & expenses | $27.2M | $29.8M | −$2.6M | -9% |
| Operating costs | $27.2M | $29.8M | −$2.6M | -9% |
| Research & development | $5.8M | $11.5M | −$5.6M | -49% |
| SG&A | $17.7M | $18.4M | −$650K | -4% |
| Operating cash sources | $78.2M | $56.6M | $21.6M | +38% |
| Share-based compensation | $4.5M | $4.9M | −$373K | -8% |
| Working capital & other | $73.7M | $51.7M | $22.0M | +42% |
| Net loss absorbed | $4.9M | $13.6M | −$8.6M | -64% |
| Operating cash flow | $73.3M | $43.0M | $30.2M | +70% |
Questions
How much did Theravance Biopharma's revenue grow year over year in Q1 2026?
Theravance Biopharma's revenue rose $2.3M (+15%) from $15.4M in Q1 2025 to $17.7M in Q1 2026.